Oragenics Net Income
| OGEN Stock | USD 0.84 0.02 2.44% |
As of the 2nd of February, Oragenics holds the Coefficient Of Variation of (678.14), risk adjusted performance of (0.1), and Variance of 15.59. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Oragenics, as well as the relationship between them.
Oragenics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 105.8267 | Earnings Share 48.21 | Quarterly Revenue Growth (0.91) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -9.5 M | -10 M | |
| Net Loss | -9.5 M | -10 M | |
| Net Loss | -12.9 M | -13.5 M | |
| Net Loss | (1.44) | (1.51) | |
| Net Income Per E B T | 0.90 | 0.74 |
Oragenics | Net Income | Build AI portfolio with Oragenics Stock |
Evaluating Oragenics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Oragenics's fundamental strength.
Latest Oragenics' Net Income Growth Pattern
Below is the plot of the Net Income of Oragenics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Oragenics financial statement analysis. It represents the amount of money remaining after all of Oragenics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Oragenics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oragenics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (10.57 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Oragenics Net Income Regression Statistics
| Arithmetic Mean | (11,905,675) | |
| Coefficient Of Variation | (49.95) | |
| Mean Deviation | 4,527,026 | |
| Median | (10,567,918) | |
| Standard Deviation | 5,946,603 | |
| Sample Variance | 35.4T | |
| Range | 24.8M | |
| R-Value | (0.38) | |
| Mean Square Error | 32.4T | |
| R-Squared | 0.14 | |
| Significance | 0.14 | |
| Slope | (443,163) | |
| Total Sum of Squares | 565.8T |
Oragenics Net Income History
Other Fundumenentals of Oragenics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Oragenics Net Income component correlations
Oragenics Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Oragenics is extremely important. It helps to project a fair market value of Oragenics Stock properly, considering its historical fundamentals such as Net Income. Since Oragenics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Oragenics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Oragenics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Oragenics diversify its offerings? Factors like these will boost the valuation of Oragenics. Anticipated expansion of Oragenics directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Oragenics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Oragenics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Oragenics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Oragenics' market price to deviate significantly from intrinsic value.
It's important to distinguish between Oragenics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Oragenics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Oragenics' market price signifies the transaction level at which participants voluntarily complete trades.
Oragenics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Oragenics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Oragenics.
| 11/04/2025 |
| 02/02/2026 |
If you would invest 0.00 in Oragenics on November 4, 2025 and sell it all today you would earn a total of 0.00 from holding Oragenics or generate 0.0% return on investment in Oragenics over 90 days. Oragenics is related to or competes with Novartis, Pfizer, Sanofi ADR, and Gilead Sciences. Oragenics, Inc. develops antibiotics for infectious diseases in the United States More
Oragenics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Oragenics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Oragenics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.16) | |||
| Maximum Drawdown | 19.9 | |||
| Value At Risk | (7.53) | |||
| Potential Upside | 4.55 |
Oragenics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oragenics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Oragenics' standard deviation. In reality, there are many statistical measures that can use Oragenics historical prices to predict the future Oragenics' volatility.| Risk Adjusted Performance | (0.1) | |||
| Jensen Alpha | (0.62) | |||
| Total Risk Alpha | (0.84) | |||
| Treynor Ratio | (1.03) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Oragenics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Oragenics February 2, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.1) | |||
| Market Risk Adjusted Performance | (1.02) | |||
| Mean Deviation | 3.0 | |||
| Coefficient Of Variation | (678.14) | |||
| Standard Deviation | 3.95 | |||
| Variance | 15.59 | |||
| Information Ratio | (0.16) | |||
| Jensen Alpha | (0.62) | |||
| Total Risk Alpha | (0.84) | |||
| Treynor Ratio | (1.03) | |||
| Maximum Drawdown | 19.9 | |||
| Value At Risk | (7.53) | |||
| Potential Upside | 4.55 | |||
| Skewness | 0.1103 | |||
| Kurtosis | 0.6169 |
Oragenics Backtested Returns
Oragenics maintains Sharpe Ratio (i.e., Efficiency) of -0.1, which implies the firm had a -0.1 % return per unit of risk over the last 3 months. Oragenics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Oragenics' Variance of 15.59, coefficient of variation of (678.14), and Risk Adjusted Performance of (0.1) to confirm the risk estimate we provide. The company holds a Beta of 0.58, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Oragenics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Oragenics is expected to be smaller as well. At this point, Oragenics has a negative expected return of -0.41%. Please make sure to check Oragenics' total risk alpha, as well as the relationship between the skewness and day median price , to decide if Oragenics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.59 |
Good reverse predictability
Oragenics has good reverse predictability. Overlapping area represents the amount of predictability between Oragenics time series from 4th of November 2025 to 19th of December 2025 and 19th of December 2025 to 2nd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Oragenics price movement. The serial correlation of -0.59 indicates that roughly 59.0% of current Oragenics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.59 | |
| Spearman Rank Test | -0.13 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Oragenics Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Oragenics reported net income of (10.57 Million). This is 103.1% lower than that of the Biotechnology sector and 115.09% lower than that of the Health Care industry. The net income for all United States stocks is 101.85% higher than that of the company.
Oragenics Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oragenics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Oragenics could also be used in its relative valuation, which is a method of valuing Oragenics by comparing valuation metrics of similar companies.Oragenics is currently under evaluation in net income category among its peers.
Oragenics Fundamentals
| Return On Equity | -1.69 | ||||
| Return On Asset | -0.71 | ||||
| Current Valuation | (7.51 M) | ||||
| Shares Outstanding | 4.17 M | ||||
| Shares Owned By Insiders | 2.38 % | ||||
| Shares Owned By Institutions | 13.17 % | ||||
| Number Of Shares Shorted | 57.84 K | ||||
| Price To Earning | (2.28) X | ||||
| Price To Book | 0.36 X | ||||
| Price To Sales | 89.28 X | ||||
| Gross Profit | (3.39 M) | ||||
| EBITDA | (10.54 M) | ||||
| Net Income | (10.57 M) | ||||
| Cash And Equivalents | 17.87 M | ||||
| Cash Per Share | 0.15 X | ||||
| Total Debt | 328.53 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 12.31 X | ||||
| Book Value Per Share | 2.38 X | ||||
| Cash Flow From Operations | (8.6 M) | ||||
| Short Ratio | 0.98 X | ||||
| Earnings Per Share | 48.21 X | ||||
| Target Price | 2.0 | ||||
| Beta | 1.11 | ||||
| Market Capitalization | 3.5 M | ||||
| Total Asset | 1.47 M | ||||
| Retained Earnings | (216.79 M) | ||||
| Working Capital | (211.88 K) | ||||
| Current Asset | 5.64 M | ||||
| Current Liabilities | 1.05 M | ||||
| Net Asset | 1.47 M |
About Oragenics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oragenics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oragenics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oragenics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Oragenics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oragenics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oragenics will appreciate offsetting losses from the drop in the long position's value.Moving together with Oragenics Stock
Moving against Oragenics Stock
| 0.75 | KOD | Kodiak Sciences | PairCorr |
| 0.72 | VRTX | Vertex Pharmaceuticals Earnings Call This Week | PairCorr |
| 0.64 | VYNE | Vyne Therapeutics | PairCorr |
| 0.64 | FBIO | Fortress Biotech | PairCorr |
| 0.53 | KPTI | Karyopharm Therapeutics | PairCorr |
The ability to find closely correlated positions to Oragenics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oragenics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oragenics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oragenics to buy it.
The correlation of Oragenics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oragenics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oragenics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Oragenics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out To learn how to invest in Oragenics Stock, please use our How to Invest in Oragenics guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Will Biotechnology sector continue expanding? Could Oragenics diversify its offerings? Factors like these will boost the valuation of Oragenics. Anticipated expansion of Oragenics directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Oragenics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Oragenics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Oragenics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Oragenics' market price to deviate significantly from intrinsic value.
It's important to distinguish between Oragenics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Oragenics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Oragenics' market price signifies the transaction level at which participants voluntarily complete trades.